Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001020066-25-000013
Filing Date
2025-02-12
Accepted
2025-02-12 11:42:47
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7686
2 EXHIBIT 1 jointfilingstatement.htm EX-1 3817
  Complete submission text file 0001020066-25-000013.txt   13561
Mailing Address SANDS CAPITAL MANAGEMENT, LLC 1000 WILSON BLVD, SUITE 3000 ARLINGTON VA 22209
Business Address SANDS CAPITAL MANAGEMENT, LLC 1000 WILSON BLVD, SUITE 3000 ARLINGTON VA 22209 703-562-4000
SANDS CAPITAL MANAGEMENT, LLC (Filed by) CIK: 0001020066 (see all company filings)

EIN.: 202830751 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Subject) CIK: 0001515673 (see all company filings)

EIN.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87964 | Film No.: 25613367
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)